A retrospective cohort study of association between therapy with bone‐modifying agents (BMAs) and survival in older women with early breast cancer patients
Latest Information Update: 06 Jul 2020
At a glance
- Drugs Alendronic acid (Primary) ; Denosumab (Primary) ; Ibandronic acid (Primary) ; Ibandronic acid (Primary) ; Risedronic acid (Primary) ; Zoledronic acid (Primary)
- Indications Advanced breast cancer; Bone metastases
- Focus Therapeutic Use
Most Recent Events
- 06 Jul 2020 New trial record
- 23 Jun 2020 Results published in the Cancer